REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2020

Apr 14, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2020-04-09

Reporting Person: Landry Robert E (EVP Finance CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-04-09	Common Stock	M	3500	$272.7	Acquired	27873	Direct
2020-04-09	Common Stock	F	2672	$508.25	Disposed	25201	Direct
2020-04-13	Common Stock	S	99	$505.6	Disposed	25102	Direct
2020-04-13	Common Stock	S	38	$506.24	Disposed	25064	Direct
2020-04-13	Common Stock	S	30	$507.45	Disposed	25034	Direct
2020-04-13	Common Stock	S	115	$508.54	Disposed	24919	Direct
2020-04-13	Common Stock	S	170	$509.45	Disposed	24749	Direct
2020-04-13	Common Stock	S	143	$510.43	Disposed	24606	Direct
2020-04-13	Common Stock	S	156	$511.59	Disposed	24450	Direct
2020-04-13	Common Stock	S	31	$512.58	Disposed	24419	Direct
2020-04-13	Common Stock	S	46	$517.71	Disposed	24373	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-04-09	Non-Qualified Stock Option (right to buy)	$272.7	M	3500	Disposed	2023-09-09	Common Stock (3500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	172	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 30 shares of Company stock on April 13, 2020 at prices ranging from $507.44 to $507.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.

F3: Represents volume-weighted average price of sales of 115 shares of Company stock on April 13, 2020 at prices ranging from $508.24 to $508.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.

F4: Represents volume-weighted average price of sales of 170 shares of Company stock on April 13, 2020 at prices ranging from $509.03 to $509.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.

F5: Represents volume-weighted average price of sales of 143 shares of Company stock on April 13, 2020 at prices ranging from $510.11 to $510.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.

F6: Represents volume-weighted average price of sales of 156 shares of Company stock on April 13, 2020 at prices ranging from $511.23 to $511.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.

F7: Represents volume-weighted average price of sales of 31 shares of Company stock on April 13, 2020 at prices ranging from $512.01 to $512.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.

F8: The stock option award vests in four equal annual installments, commencing one year after the date of grant.